Although multi-antigen targeting may represent a suitable strategy to improve on-tumor specificity and to minimize risk of antigen escape, further comparative data is needed to assess the relationship between clinical response profiles of treated CD19- patients and their transduced T-cells. This evidence concerns the gene CD19 and neoplasm.